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Introduction 
Unintended pregnancy affects many women’s quality of life. Data suggest that unplanned 
pregnancies are a result of incorrect, inconsistent, or nonuse use of an effective contraceptive 
method (Smith, Jozkowski, & Sanders, 2014). A highly effective option for contraception is an 
intrauterine device, or IUD. The IUD is touted, by physicians and researchers alike, as one of the 
most effective methods for preventing pregnancy (AGOG). They are reversible, long-acting, and 
are increasingly considered a contraceptive method that can help lower the extremely high rate of 
unintended pregnancy in the United States which is currently hovering just below 50%  (Finer & 
Zolna, 2011).  
IUDs are a part of a group of contraceptive methods called LARCs or long-acting 
reversible contraception. A specific type of IUD that functions on a hormonal mechanism are 
called intrauterine systems or IUSs. LARCs are widely considered to be the most effective 
reversible contraceptive methods and include IUDs and the subdermal implant. LARC methods 
have been shown to have method failure rates close to tubal sterilization. IUDs have failure rates 
that are more in line with perfect use failure rates than with rates that account for human error 
(Stoddard, McNicholas, & Peipert, 2011). Unfortunately, few women in the United States are 
using IUDs (Stoddard, McNicholas, & Peipert, 2011). Despite being suggested as a first-line 
contraceptive method for women and adolescents (ACOG), only 5.5% of women in the United 
States who use contraceptives rely on IUDs as their primary method. This low rate is shocking 
when compared to the rest of the world where countries such as Norway and China have rates as 
high as 27% and 30% respectively (Gomez & Clark, 2014; Stoddard et al., 2011). When asked in 
2002, as much as 39% of women in the United States reported not knowing anything about IUDs 
(Gomez & Clark, 2014; Stoddard et al., 2011). Because the United States is a nation with an 
extremely high incidence of unintended pregnancy, the lack of understanding regarding one of 
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the most effective forms of birth control is unsettling. The low use of IUDs in the United States 
can most likely be attributed to a lack of trained providers, high initial cost, and inaccurate 
knowledge both among clinicians and patients (Stoddard, McNicholas, & Peipert, 2011). 
According to Smith and colleagues (2014), “identifying the factors that may contribute to 
women’s nonuse or inconsistent use of hormonal contraception is extremely important for the 
continued promotion of planned and timed pregnancies in the United States” (p. 469). One of the 
major factors that may contribute to nonuse, inconsistent use, or discontinuation of a method are 
the method’s effects on sexual function. Women have reported that hormonal fluctuations and 
effects on sexual function as contributing factors to inconsistent or nonuse of a method (Sanders, 
Graham, Bass, Bancroft, 2001). There exists a plethora of literature on the effects of oral 
contraceptive pills (OCPs) on hormones and sexual function, but there is not a comparable 
amount of data on the effects of IUDs on the same parameters. The gap in the literature leads to 
the question: what is the effect of hormonal IUDs on hormone fluctuations and sexual function? 
Answering the above question is imperative to improving knowledge around IUD usage. 
In order to reduce the number of unplanned pregnancies, strategies to improve consistent use of 
contraception by young women and teenagers must be determined. Because women who had 
heard about the IUD from a healthcare provider were 2.7 times more likely to be interested in 
using the method, enhancing knowledge and determining a strategy to improve consistent 
contraceptive use are linked (Fleming, Sokoloff, & Raine 2010). Clinicians should be 
knowledgeable about IUDs and encouraged to talk to women about them. To promote IUD use  
through conversation, providers must fully understand the side effects of IUDs including their 
effects on hormones and sexual function.  
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Literature Review 
 Unintended pregnancy and effective contraceptive methods to help women prevent 
pregnancy have be prevalent topics in public health literature. As such, a plethora of research has 
been established to determine the most effective methods of preventing pregnancy. Within the 
current literature, IUDs provide a notable contrast to most other reversible contraceptive methods 
such as the oral contraceptive pill (OCP) because they are more effective. Unlike OCPs, IUDs 
present no risk of failure due to error, poor adherence, or noncompliance (Anderson et al. 2014). 
As such, IUDs have efficacy rates close to those of tubal sterilization at less than 1%, while 
typical oral contraceptive efficacy rate is 8-9% (Stoddard, McNicholas, & Peipert, 2011). No 
attention is required on the part of an IUD user after insertion until time for removal, making 
IUDs a significantly more effective method than OCPs when considering user error.  
Despite their efficacy, very few women in the United States use IUDs as their primary 
method of contraception. Rates for IUD usage among women in the United States who are 
practicing birth control hover around 5.5% (Stoddard, McNicholas, & Peipert, 2011). The low 
rate of IUD use in the United States is likely related to a number of factors; however, the most 
notable is lack of provider knowledge (Anderson et al. 2014). Because very little information 
exists on the effects of hormonal IUDs on sex-hormone levels and the subsequent effects on 
sexual function, providers cannot have appropriate conversations with women regarding IUDs 
and their sexual health. Lack of provider knowledge regarding IUDs and sexual function is 
important because sexual function is a primary reason that many women discontinue a 
contraceptive method. Sanders et al. (2014) found that, in a cohort of women using oral 
contraceptive pills, 8% of women who discontinued or switched pills did so because of sexual 
side effects. Women who are using or may be interested in using IUDs will have questions about 
potential sexual side effects that the devices may have. Additionally, women are more likely to 
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consider using an IUD if they hear about the method from their providers (Fleming, Sokoloff, & 
Raine 2010). Studies also indicate that providers who have access to more evidence-based 
information are significantly more likely to offer information about IUDs to their patients 
(Fleming, Sokoloff, & Raine 2010), demonstrating that providers need to be equipped with the 
knowledge to initiate conversations about IUDs; properly answer their patients’ questions about 
IUDs, hormones, and sexual function; and address their patients’ concerns regarding IUDs. 
Although there is a lack of research surrounding hormonal IUDs, sex-hormone levels, 
and sexual function, there is a large amount of data covering oral contraceptive methods and 
their effects on hormones and sexual function. Understandably, more research has been done on 
hormone levels and sexual function in women taking oral contraceptives. Oral contraceptives are 
the most popular form of reversible contraception used in the United States with approximately 
80% of women using oral contraceptives at some point in their lifetimes (Rosenberg, Waugh, 
1998). However, because compliance is a major contributor to the lower effectiveness rate of 
oral contraceptives, more research should be done to level the playing field in the literature 
between IUDs and OCPs to equip clinicians and public health workers with the proper 
knowledge and abilities to properly address unintended pregnancy.  
Given their hormonal nature, it is understandable that many researchers questioned, early 
on, the effects that oral contraceptives would have on hormones. In general, combined oral 
contraceptives decrease ovarian production of testosterone (Burrows, Basha, Goldstein 2012). 
because they inhibit luteinizing hormone (LH). The estrogen component of combined oral 
contraceptives leads to an increased production on sex hormone binding globulin (SHBG) which 
in turn decreases free testosterone and other androgens (Burrows, Basha, Goldstein 2012). New 
pills, especially, have been shown to significantly decrease free testosterone and increase SHBG 
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levels (Shah & Hoffstetter 2010). Studies centered around OCPs conclude that their effects on 
androgens specifically, can affect lubrication and potentially affect arousal and desire. In a study 
conducted by Wahin-Jocobsen and colleagues (2017), lower levels of free testosterone and 
androstenedione was associated with low sexual desire; however, the effect of a hormonal IUDs 
on testosterone and androstenedione levels is unknown. In one of the earliest studies done on 
modern combined oral contraceptives (COCs) and their effects on sexual function, women who 
were using oral contraceptives were significantly more likely to report decreased vaginal 
lubrication (Burrows, Basha, Goldstein 2012). The increase in reporting of vaginal dryness 
among oral contraceptive users may be explained by the fact that androgens are required for the 
early aspects of mucous formation (Burrows, Basha, Goldstein 2012).  In a cross-sectional study 
of 349 pre- and postmenopausal women, Davison et al. (2008) found that women who were 
using or had used a COC were less likely than other women to report sexual thoughts and sexual 
interest. These women also reported fewer days of sexual activity per month than nonusers 
(Davison et al. 2008). Studies have also linked COCs to vestibular pain and have concluded that 
taking COCs may predispose women to vestibular pain. One study found that the likelihood of 
developing vestibulodynia was highest in women who had been taking the pill the longest and 
women who had begun taking the pill at a younger age (Burrows, Basha, Goldstein 2012). 
Literature also exists that explores the effects of Depot Medroxyprogesterone Acetate (DMPA) 
on sexual function. DMPA is a contraceptive method that is considered a monophasic method. 
DMPA is an injectable progestin (Burrows, Basha, Goldstein 2012). Like the IUD, DMPA is a 
LARC and provides reliable pregnancy prevention. Nelson (1996) found that around 5.8% of 
women who rely on DMPA as their contraceptive method report lost or decreased libdo; 
however other authors such as Fortenberry & Hansel (2011) found no difference in sexual desire 
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compared with nonusers, indicating that more research needs to be done to determine the effects 
of monophasic, hormonal methods such as the DMPA and the hormonal IUD. 
 The connection between hormonal IUDs and females’ sex-hormone levels has not been 
established; however, the system under which hormonal IUDs function is well understood. 
Hormonal IUDs work based on the levonorgestrel intrauterine system. Levonorgestrel (LNG) is 
a synthetic progestin that thickens cervical mucus and inhibits sperm motility (Stoddard et al., 
2011). hormonal IUDs, referred to as IUSs when talking specifically about the hormonal system, 
release very low doses of progestins at a constant, daily dose (Abou-Setta, Attia, Ibrahim 2013). 
The term, IUS is used to specify that the IUD, with is an al-encompassing term that includes 
non-hormonal and hormonal devices, that is being referred to functions on a hormonal system. 
There are several different IUSs that are currently available. They are Mirena, Kyleena, and 
Skyla. Each one releases a different daily dose of LNG into the uterine cavity; however, they are 
all constant and none exceed 20 micrograms per day (Abou-Setta, Attia, Ibrahim 2013). 
Although not in IUSs specifically, synthetic progestins, like LNG, have been shown to suppress 
sex drive. They have even been used to suppress sexual urges in men (Smith et al., 2014). The 
effects that the low dose progestins may have on naturally occurring hormone fluctuations and 
the subsequent effects on sexual function in women who use IUSs have not been established, 
however.  
In conclusion, the IUS is an effective contraceptive system that can be used to reduce the 
stubbornly high rates of unintended pregnancy in the United States; however, little research 
exists to equip healthcare providers and promoters with knowledge surrounding IUS use, sex-
hormone fluctuations, and sexual function. Women need their healthcare providers to initiate 
conversations around hormonal IUDs and practitioners need more information to feel confident 
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talking about hormonal IUDs (Fleming, Sokoloff, & Raine 2010). Research that has been done 
on OCP users suggests that synthetic hormones, including the progestins that are used in low 
doses in hormonal IUDs, affect naturally occurring hormone levels as well as sexual function 
(Burrows, Basha, Goldstein 2012). This study focused on hormonal fluctuations experienced by 
IUS users and the effects of various fluctuation levels on sexual function domains such as desire 
and lubrication which have been shown to be associated with hormone levels and hormonal 
contraceptive methods. The purpose of the study was to examine sex-hormone fluctuations in 
IUS users and sexual function in relation to the observed sex-hormone fluctuations in order to 
bridge the gap in literature surrounding IUSs.  
Methods 
Participants 
This study consisted of women (N=19, aged 18 – 31 years) who had an IUD, referred to 
as IUS when talking specifically about hormonal IUDs, (Mirena, Skyla, or Kyleena) for at least 
12 months prior to participation in the study. Participants were all within 80% - 130% of ideal 
body weight, had a regular sex partner, and were not taking any medications known to impact 
sexual function or sex hormones, such as SSRIs. The participants were all white women and had, 
on average, 3.88 sexual encounters (solitary and partnered) per week.  
Procedures  
Each participant initially reported to the lab for a screening meeting to ensure that she 
met the inclusion criteria for body weight (80%-130% of ideal body weight). At this initial visit, 
the participants also complete two surveys: a demographic survey and a survey that was also 
given at each subsequent visit. Additionally, participants provided a blood sample. After the 
initial visit, participants reported to the lab once per week for three additional weeks to have 
blood drawn and complete the survey. The survey measured sexual function by using the Female 
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Sexual Function Index (FSFI) (Rosen et al. 2000). The FSFI is a multidimensional instrument 
that assesses sexual function in the prior week based on self-reports (Rosen et al. 2000). It 
contains six domains; desire, arousal, lubrication, orgasm, satisfaction, and pain, and it is 
designed for females with a regular sex partners who experience sexual activity during the time 
period studied (Rosen et al. 2000). While completing the survey, participants were also engaging 
in a 15-minute sitting period to allow for blood volume to stabilize. After the survey and the 
sitting period were completed, the blood was collected using a 8.5 mL serum separating tube. 
The blood sample was allowed to clot for 20 minutes. After the clotting period, the blood was 
put into a centrifuge for 15 minutes at 2200 G and 20 degrees Celsius. When it was removed 
from the centrifuge, the serum had separated to a point where it was able to be removed and 
placed, evenly, into six cryotubes and frozen at -80 degrees Celsius. The serum remained frozen 
until later analysis.  
 After reaching nineteen participants with four data collections for each participant (once 
per week for four weeks), the serum was thawed for use in the enzyme-linked immunosorbent 
assays (ELISAs). Multiple ELISAs were run to measure the sex hormones present in the blood 
serum. The ELISA method provided readings on estradiol, progesterone, testosterone, and 
androstenedione. Data collection over a one-month time period helped to prevent many 
psychosocial variables from impacting results. All participants remained in steady relationships 
and were less likely to have a drastic change in their health or lives; therefore, the sexual 
function relationship, presumably, was to hormones specifically as compared to psychosocial 
variables.  
Data Analysis 
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Data were analyzed using a linear mixed model in the R programming language using the 
lme4 package. When a significant relationship between hormone concentration and any measure 
of sexual function was detected follow-up pairwise comparisons were made using the emmeans 
package. After the data were analyzed in the R program, data were evaluated using an analysis of 
variance (ANOVA). An ANOVA was run on each outcome variable from the FSFI (arousal, 
satisfaction, lubrication, desire, and orgasm) as the dependent variable and hormone levels 
(testosterone, estradiol, progesterone, and androstenedione) as the independent variable. When a 
significant ANOVA effect was detected, pairwise comparisons were conducted. Significance 
was set at an alpha of less than .05. Marginal significance was set at an alpha of less than .051 to 
.09.  
Results 
 There were no significant associations between testosterone and the outcome variables: 
arousal [F(2.25,24.79)=0.62, p = .56], satisfaction [F(2.40,26.44)=0.19, p = .86], lubrication 
[F(2.08,22.86)=0.29, p = .76], desire [F(2.35,25.87)=0.14, p = .90], or orgasm 
[F(2.49,27.36)=0.71, p = .53]. There were also no significant associations between estradiol and 
the outcome variables: arousal [F(2.37,42.59)=0.63, p = .56], satisfaction [F(2.44,43.96)=0.93, p 
= .42], lubrication [F(2.55,45.86)=0.14, p = .92], desire [F(2.45,44.04)=0.51, p = .64], or orgasm 
[F(2.70,48.56)=0.42, p = .72]. Additionally, there were no significant associations between 
progesterone and the outcome variables: arousal [F(2.11,29.59)=1.47, p = .25], satisfaction 
[F(2.60,36.44)=0.70, p = .54], lubrication [F(2.26,31.65)=1.06, p = .37], desire 
[F(1.86,26.07)=1.26,  p = .30], or orgasm [F(2.61,36.59)=0.64, p = .57]. Androstenedione had a 
significant association with changes in vaginal lubrication [F(1.77,31.92)=5.96, p = .008], and a 
marginally significant association with fluctuations in arousal [F(2.13,38.29)=3.00, p = .06] and 
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orgasm [F(1.96,35.29)=3.14, p = .06]. Androstenedione had no association with satisfaction 
[F(2.61,47.02)=1.02, p = .39] or desire [F(2.40,43.24)=1.30, p = .29].  
Discussion  
 The current study hypothesized that there would be an association between varying levels 
of androstenedione and sexual function, specifically lubrication: as androstenedione increased, it 
was expected that lubrication and the other sexual function outcome variables would also 
increase. The study also hypothesized that as progesterone increased, sexual function would 
decrease and that there would be no association between estradiol and testosterone and sexual 
function. Literature points toward an association between androgens and sexual function in OCP 
users (Burrows, Basha, Goldstein 2012); however, the directionality of the relationship is 
ambiguous for estradiol and testosterone. Additionally, the study hypothesized that IUS users 
would experience sex-hormone fluctuations despite the constant, daily, low dose of LNG 
released into the uterine cavity each day over the course of their IUS use (Abou-Setta, Attia, 
Ibrahim 2013). The null hypothesis for all associations was that there would be no association; 
therefore, for androstenedione, the null hypothesis was rejected and for all other sex-hormones, 
the null hypotheses failed to be rejected. 
 Although the null hypothesis for androstenedione was rejected, the outcome was slightly 
different than expected. The increase in androstenedione did lead to a subsequent increase in 
several sexual function domains (lubrication, desire, arousal, and orgasm); however, the data for 
androstenedione followed a cubic relationship meaning that at a certain point, an increase in 
androstenedione led to decreased sexual function domains. For IUS users, this might mean that if 
they are more sensitive to variations in androstenedione, they could experience varying sexual 
function effects.  
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The relationship between androstenedione and sexual function is important because it can 
be used to better inform potential IUS users on side effects as well as help clinicians and women 
make decisions on what methods are best considering their reactions to androstenedione 
fluctuations. Better informing clinicians and women on effective contraceptive methods will 
potentially help to reduce the number of unintended pregnancies by making both the prescribers 
and the users feel more confident in their methods. It may also contribute to consistent, 
continued use of IUSs because the side effects will be better understood. Additionally, the fact 
that many of the hormone fluctuations experienced by IUS users were not associated with sexual 
function can also be used to help better inform potential users. Because many women have 
reported hormonal fluctuations and effects on sexual function as contributing factors to 
inconsistent or nonuse of a method, being able to understand specific effects on sexual function 
will be important in promoting consistent use. (Sanders, Graham, Bass, Bancroft, 2001). If 
clinicians are able to confidently tell women that their sexual function should not be affected or 
are able to tell women how their sexual function will be affected, more women may choose to 
use an IUS, ultimately helping to reduce numbers of unintended pregnancies.  
In comparison to the research conducted on OCPs and sexual function, the results from 
this study suggest that IUS users experience fewer changes in sexual function. Given the 
prevalence of negative sexual function effects of OCPs, the IUS may be a preferable choice for 
women who have experienced negative effects during OCP use. Physicians are encouraged to 
discuss sexual side effects of all contraceptive options with patients, along with other effects, to 
provide the most comprehensive information for patients in their decisions about contraceptive 
methods.  
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Limitations 
 As one of the first studies to assess the effects of IUS on sexual function, this study 
contributes to the literature and knowledge on this topic, but is not exempt from limitations such 
as a small sample size, the limited time frame (4 weeks), and the inconsistency in some 
participants experiencing a menses while others did not during that time frame. Further research 
is needed to better understand the long term associations of IUS use with sexual function, 
including with a larger, more diverse sample of women, who have been using the systems for 
various amounts of time. Future research should aim to compare different IUS brands (e.g., 
Mirena, Skyla, Liletta, etc.), particularly those that may have differing amounts of LNG. 
Additionally, further research is needed to specifically compare IUS users and nonusers to better 
associate the hormone fluctuations and sexual function with the IUS.  
Tables and Figures 
 
 
Figure 2: Five of the FSFI subscale scores presented from the week with the lowest 
androstenedione levels to the highest level of androstenedione levels 
 
 
SEX-HORMONE FLUCTUATIONS AND THEIR EFFECTS                                                   14 
  
 
 
Figure 1: Rank-ordered from lowest to highest hormone levels of participants throughout each 
week of the study. The labeling does not correspond with the data collection (i.e. Week 1 does 
not equal visit 1). 
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